title: Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.
abstract: Lower fluctuation, i.e., lower peak-to-trough plasma-concentration variation at steady-state pharmacokinetics, has several advantages for the treatment of schizophrenia with antipsychotics. The reduction of peak concentration can decrease the risk of dose-dependent side effects, such as extrapyramidal symptom and somnolence, and by contrast the increase in trough concentration can decrease the incidence of lack of efficacy due to subtherapeutic drug concentration. Using a one-compartment simulation technique with pharmacokinetic parameters of each atypical antipsychotic collected from package inserts, the fluctuation index was calculated. Among the antipsychotics, the indices varied from 0.018 to 1.9, depending on dosing regimens, formulations and several pharmacokinetic properties. The order of simulated fluctuation index is active-moiety aripiprazole (b.i.d.) <paliperidone extended release (q.d.) <active-moiety aripiprazole (q.d.) <active-moiety blonanserin (b.i.d.) <olanzapine (q.d.) <active-moiety risperidone (b.i.d.) <amisulpride (q.d.) <active-moiety risperidone (q.d.) <quetiapine (t.i.d.) <perospirone (t.i.d.) <quetiapine (b.i.d.). Since the fluctuation indices of aripiprazole and paliperidone extended-release are less than 0.2, which predominantly attributed to their long elimination half-lives, aripiprazole and paliperidone extended-release may have advantages in that the plasma concentration could be kept within appropriate therapeutic range.
authors: All from the CNS Department, Scientific Affairs Division, Janssen Pharmaceutical K.K., Tokyo Japan.
authors: Akihide
authors: A
authors: Wakamatsu
authors: Kazuo
authors: K
authors: Aoki
authors: Yojiro
authors: Y
authors: Sakiyama
authors: Takashi
authors: T
authors: Ohnishi
authors: Makoto
authors: M
authors: Sugita
keywords: Atypical antipsychotics; fluctuation index; one-compartment simulation; pharmacokinetics
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):132-9
references: 16386474
references: Am J Psychiatry. 2001 Mar;158(3):360-9
references: 11229973
references: Am J Cardiol. 2006 Oct 2;98(7A):39L-45L
references: 17023231
references: Neuropsychopharmacology. 2002 Aug;27(2):248-59
references: 12093598
references: N Engl J Med. 1996 Jan 4;334(1):34-41
references: 7494570
references: Innov Clin Neurosci. 2012 Jul;9(7-8):17-23
references: 22984648
references: J Clin Psychopharmacol. 2011 Jun;31(3):318-25
references: 21508857
references: Mol Psychiatry. 2007 Oct;12(10):904-22
references: 17667958
references: Arch Gen Psychiatry. 1974 Jul;31(1):67-72
references: 4151750
references: Can J Psychiatry. 2002 Feb;47(1):27-38
references: 11873706
references: Biol Psychiatry. 2001 Dec 1;50(11):884-97
references: 11743943
references: Schizophr Bull. 1997;23(4):637-51
references: 9366000
references: J Clin Psychiatry. 2003;64 Suppl 16:18-23
references: 14680415
references: Eur J Pharmacol. 2008 Apr 28;584(2-3):318-27
references: 18325493
references: J Clin Psychiatry. 1997;58 Suppl 10:55-62
references: 9265918
references: Eur Neuropsychopharmacol. 2006 May;16(4):233-40
references: 16326078
references: Clin Ther. 2004 May;26(5):649-66
references: 15220010
references: Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73
references: 8935801
references: Encephale. 2005 Sep-Oct;31(5 Pt 1):609-15
references: 16598965
references: Ther Clin Risk Manag. 2008 Oct;4(5):1035-46
references: 19209284
references: Br J Clin Pharmacol. 2010 Dec;70(6):815-24
references: 21175437
references: Drug Saf. 2000 Mar;22(3):195-214
references: 10738844
references: Schizophr Res. 2004 Sep 1;70(1):91-100
references: 15246468
references: Curr Med Res Opin. 2006 Oct;22(10):1879-92
references: 17022845
references: Psychopharmacology (Berl). 2008 Apr;197(2):229-35
references: 18058087
references: Psychol Med. 1992 Aug;22(3):787-97
references: 1357703
references: Drugs. 2008;68(16):2269-92
references: 18973393
references: Psychopharmacology (Berl). 1990;101(1):132-6
references: 1971445
references: Int Clin Psychopharmacol. 1997 Feb;12 Suppl 1:S37-42
references: 9179642
references: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):199-204
references: 18948162
references: J Psychopharmacol. 2010 Jul;24(7):1011-8
references: 19825908
references: Eur J Clin Pharmacol. 2010 Aug;66(8):797-803
references: 20358189
references: J Clin Psychopharmacol. 2011 Aug;31(4):497-502
references: 21694629
references: J Clin Psychiatry. 1998;59 Suppl 3:21-5
references: 9541334